Skip Navigation

Study findings suggest that PD patients of older age (mean 78.3 years) with longer disease duration (mean 12.7 years) are particularly susceptible to COVID-19 with a substantially high mortality rate (40%). Those on advanced therapies, such as deep brain stimulation or levodopa infusion therapy, seem specially vulnerable and a mortality rate of 50% among our four such cases is of concern.​

Read more in Movement Disorders 2020 Jun. Vol. 35(6); 905-908

doi: 10.1002/mds.28104

Back to top